Modulation of T-type Ca2+ channels by Lavender and Rosemary extracts

PLoS Onev.12(10); 2017PMC5658086 PLoS One. 2017; 12(10): e0186864. Published online 2017 Oct 26. doi: 10.1371/journal.pone.0186864 PMCID: PMC5658086 Chaymae El Alaoui, Investigation, Writing – original draft,1,2,3 Jean Chemin, Formal analysis, Investigation,1,2 Taoufiq Fechtali, Supervision,3 and Philippe Lory, Conceptualization, Funding acquisition, Resources, Writing – original draft, Writing – review & editing1,2,* J. David Spafford, Editor Author information ► Article notes ► Copyright and License information ► Go to: Abstract Medicinal plants represent a significant reservoir of unexplored substances for early-stage drug discovery. Of interest, two flowering Mediterranean plants have been used for thousands of years for their beneficial effects on nervous disorders, including anxiety and mood. However, the therapeutic potential of these plants regarding their ability to target ion channels and neuronal excitability remains largely unknown. Towards this goal, we have investigated the ability of Lavender and Rosemary to modulate T-type calcium channels (TTCCs). TTCCs play important roles in neuronal excitability, neuroprotection, sensory processes and sleep. These channels are also involved in epilepsy and pain. Using the whole-cell patch-clamp technique, we have characterized how Lavender and Rosemary extracts, as well as their major active compounds Linalool and Rosmarinic acid, modulate the electrophysiological properties of recombinant TTCCs (CaV3.2) expressed in HEK-293T cells. Both the methanolic and essential oil extracts as well as the active compounds of these plants inhibit Cav3.2 current in a concentration-dependent manner. In addition, these products also induce a negative shift of the steady-state inactivation of CaV3.2 current with no change in the activation properties. Taken together, our findings reveal that TTCCs are a molecular target of the Lavender and Rosemary compounds, suggesting that inhibition of TTCCs could contribute to the anxiolytic and the neuroprotective effects of these plants. Go to: Introduction Medicinal plants have been identified and used throughout human history [1]. Because of their ability to synthesize a wide variety of chemical compounds (alkaloids, polyphenolics, terpenoids, fatty acids and lipids, etc.) either for their normal development or against stressful and threatening conditions, they have been suggested to be an interesting pharmaceutical industry. Moreover, because of the potential side and adverse effects of synthetic drugs, scientists interested in drug discovery have turned their attention to herbal medicines as effective lead compounds for the management of health ailments including inflammatory, cardiovascular and neurological disorders[2, 3]. It’s worth noting that 49% of the new chemical drugs that were introduced between 1991 and 2002 had a natural origin witnessing the popularity of medicinal plants use worldwide [4]. Lavender and Rosemary are the most popular medicinal plants cultivated and grown nowadays. Native to the Mediterranean basin and Southern Europe, they have been used either dried or as essential oil for a variety of culinary, cosmetic and therapeutic purposes [5–7]. Studies have reported the existence of approximately 28 species and over than 200 varieties of Lavender (Lavandula sp.). The genus Lavender belongs to the Labiatae/Lamiaceae family and is divided into four main species: Lavandula latifolia, Lavandula angustifolia (LA); Lavandula stoechas (LS) and Lavandula x intermedia [8]. Lavender essential oil is generally produced by steam distillation and contains a complex mixture of mono- and sesquiterpenoid alcohols, esters, oxides, and ketones, in which the major components are the monoterpenoids linalool and linalyl acetate [5]. Lavender oil was suggested to possess anticonvulsant, anxiolytic, analgesic and neuroprotective properties [5, 9–11]. Rosemary (Rosmarinus officinalis, RO) is one of the most interesting medicinal plants known for its promising medicinal use. Rosmarinus officinalis (Lamiaceae) oil consists of high percentages of biologically active compounds such as phenolic acids (Rosmarinic acid, chlorogenic acid), phenolic diterpenes (e.g. carnosic acid, carnosol), and flavonoids (e.g. derivatives of apigenin and luteolin) [12, 13]. A developing body of evidence suggests Rosemary to be a powerful remedy for various medical purposes thanks to its anti-oxidant, antinociceptive, and neuroprotective properties [14–17]. Rosmarinic acid, one of the major components of RO, is a polyphenolic compound and has been shown to possess anti-inflammatory, anti-oxidant and anxiolytic/antidepressive-like properties [18–20]. The precise mode of action of these two medicinal plants remains unclear. Studies to unveil the molecular mechanisms implicated in their therapeutical effects have recently suggested the modulation of GABAergic [21], serotonergic neurotransmission [22], as well as voltage-gated calcium channels including high voltage-activated (HVA) calcium channels by Lavandula angustifolia [10]. However, it has not been investigated whether Lavender (Lavandula angustifolia and Lavandula stoechas) and Rosemary can also affect low voltage-activated (LVA), T-type calcium channels (TTCCs). Compared to HVA calcium channels, TTCCs are specifically activated by small membrane depolarization that allow calcium entry near the cell membrane resting potential [23, 24]. Heterogeneity in the functional properties of TTCCs is supported by molecular studies that have described three genes encoding these channels: the CaV3.1, CaV3.2, and CaV3.3 subunits [23, 25]. These subunits are differentially expressed throughout the body, especially in the brain [26]. TTCCs are broadly involved in many physiological processes including sleep [27], proliferation [28, 29], neuronal firing, epilepsy [30, 31] and pain [32, 33]. Furthermore, recent studies have reported TTCCs to be an interesting molecular target for various natural substances like bioactive lipids and lipoaminoacids [34–36], toxins [37] and natural products from plants including the genera Cannabis, Curcuma and Syzygium [38–40]. In the present study, we have searched for plant extracts modulating TTCCs and we describe the pharmacological inhibition of TTCCs by Lavender and Rosemary using Cav3.2 channels expressed in HEK-293T. Go to: Materials and methods Ethics statement Lavandula stoechas, Rosmarinus officinalis, Ricinus cummunis and Citrullus colocynthis were collected at National Institute of Agronomic Research (INRA), Agadir, Morocco. No specific permissions were required for these locations/activities. The botanical identity of each plant was determined and authenticated by Dr. R. Bouharroud, taxonomist at INRA, Agadir, Morocco. Methanolic extraction protocol Fresh plant materials were dried at 40°C during 48 to 96 hours, then homogenized to fine powder by grinding and sieving until the stabilization of weight. 20 g of dried plant materials were extracted with 200 ml of pure methanol and kept on a rotary shaker for maceration for a total duration of 72h. Thereafter, the extracts were filtered and evaporated to dryness in Rotavapor® vacuum (60 rpm at 40°C). The final extracts were stored at 4°C for further studies. Plant essential oil and active principles Essential oils of Lavandula steachas, Lavandula angustifolia Miller and Rosmarinus officinalis were purchased from Vitalba (Sartène, France). Rosmarinic acid (RA) and Linalool were purchased from Sigma-Aldrich. Cell culture and transfection protocols HEK-293T cells stably expressing the CaV3.2 channels isoform (kindly provided by Dr. E. Perez-Reyes, University of Virginia) were cultivated in Dulbecco’s Modified Eagle’s Medium supplemented with GlutaMax, 400μg/ml G418 (Life Technologies) and 10% fetal bovine serum (Invitrogen). In some experiments, HEK-293T cells transfection with plasmids expressing human CaV3 constructs was performed using jet-PEI (QBiogen) with a DNA mix containing 0.5% of a GFP encoding plasmid and 99.5% of the Cav3 constructs. Two days after transfection, HEK-293T cells were dissociated with Versene (Invitrogen) and plated at a density of ~35x103 cells in 35 mm Petri dish for electrophysiological recordings performed the following day. Electrophysiological recordings Whole-cell calcium currents were recorded at room temperature using an Axopatch 200B amplifier (Molecular Devices). For recording macroscopic T-type calcium currents, the extracellular solution contained the following (in mM): 135 NaCl, 20 TEACl, 2 CaCl2, 1 MgCl2, and 10 HEPES (pH adjusted to 7.25 with KOH, ~330 mOsm). Borosilicate glass pipettes have a typical resistance of 1.5–2.5 MOhm when filled with the internal solution containing the following (in mM): 140 CsCl, 10 EGTA, 10 HEPES, 3 Mg-ATP, 0.6 GTPNa, and 3 CaCl2 (pH adjusted to 7.25 with KOH ~315 mOsm). Recordings were filtered at 2 kHz. During the CaV3.2 current recordings, the chamber was constantly perfused (~100 μl/min) with the control or with the drug solutions using a gravity-driven homemade perfusion device. Data were analyzed using the pCLAMP9 (Molecular devices) and GraphPad Prism (GraphPad) softwares. The dose-response curves were obtained from fitting data to the Hill equation, I/IMAX = 100/(1+10^((LogIC50-Log[compound])*HillSlope). Current-voltage (I-V) curves were fitted using a combined Boltzmann and linear Ohmic relationships, where I = Gmax x (Vm-Vrev)/(1+exp((Vm-Vm0.5)/slope factor)). Correspondingly, steady-state inactivation curves were fitted using the Boltzmann equation where I/Imax = 1/(1+exp((Vm-Vm0.5)/slope factor). Statistical analysis Results are presented as the mean ± SEM, and n is the number of cells used. Statistical significance was evaluated by Student’s unpaired t-test (* P<0.05, ** P<0.01 and *** P<0.001) Go to: Results Modulation of CaV3.2 calcium channels by medicinal plant methanolic extracts In a first set of experiments, we tested the ability of several Mediterranean medicinal plants to modulate TTCCs. These experiments were performed using recombinant CaV3.2 channels. CaV3.2 channel modulation was determined by measuring the T-type current in whole cell configuration on cells stepped from -80 to -30 mV following superfusion of the extracts at a concentration of 30 μg/ml. Fig 1 illustrates the efficacy of four methanolic plant extracts by showing typical CaV3.2 current trace recordings and the corresponding time plots. Application of Lavandula stoechas (LS) inhibited significantly CaV3.2 channels (Fig 1A and 1B). The average current inhibition induced by 30 μg/ml of LS was 85% (I/Ictrl = 15 ± 5.2% p<0.01, n = 6). LS developed a fast inhibitory effect that did not readily reverse upon wash-out. Similarly, a 42% inhibition (I/Ictrl = 68 ± 2% p<0.01, n = 6) was obtained following application of the methanolic extract of Rosmarinus officinalis (RO) on CaV3.2 currents (Fig 1C and 1D). On the contrary, no significant inhibition was obtained after the application of Ricinus cummunis (RC) (Fig 1E and 1F, I/Ictrl = 95.7 ± 1.5%, n = 7) and Citrullus colocynthis (CC) extracts (Fig 1G and 1H, I/Ictrl = 95.4 ± 2.1%, n = 6). These data led us to further investigate the efficacy of Lavandula and Rosmarinus species to modulate CaV3.2 channels. Fig 1 Fig 1 Modulation of CaV3.2 channels by medicinal plant methanolic extracts. CaV3.2 channel inhibition by Lavandula species and Linalool is concentration-dependent Next, we characterized the effect of two Lavandula species essential oils; Lavandula stoechas (LS), Lavandula angustifolia Miller (LA) and their active principle Linalool. CaV3.2 current recordings were performed during application of increasing concentrations of LS, LA and Linalool (Fig 2). T-type current inhibition by these three compounds was concentration-dependent. Analysis of the dose-response curve after treatment with LS essential oil revealed IC50 values of 16.9 ± 2.9 μg/ml (n = 7) with a Hillslope value of 0.9 ± 0.1 (Fig 2A). TTCCs were also inhibited by serial concentrations of LA Miller essential oil solutions (Fig 2B). The IC50 value for LA Miller inhibition of CaV3.2 currents was 34.1 ± 2.9 μg/ml (Fig 2B, n = 8) with a Hillslope factor of 1.9 ± 0.4. For CaV3.2 current inhibition by Linalool, the IC50 value was 84 ± 8.8 μM (~12.6 μg/ml) with a Hillslope factor of 1.01 ± 0.08 (Fig 2C, n = 7). Fig 2 Fig 2 Inhibition of CaV3.2 channel by Lavandula essential oils and Linalool. Effects of Lavandula essential oils and Linalool on CaV3.2 channel activation Inhibition of CaV3.2 channels by Lavender and its natural constituent Linalool may be related to specific modifications in CaV3.2 channel gating properties. Hence, we investigated whether TTCC inhibition by Lavender could be related to change in channel availability or activation properties. Toward this goal, the inhibitory effect of these natural compounds on CaV3.2 current was studied for a wide range of depolarizing test potentials (TPs) from -80 to +10 mV. Representative CaV3.2 current traces before and after the application of 30 μg/ml LS are shown in Fig 3A (top and bottom panels respectively), as well as the corresponding current-voltage (I-V) curves (Fig 3B). These average I-V curves show that 30 μg/ml of LS inhibit the amplitude of CaV3.2 currents similarly at all membrane potentials (Fig 3B, n = 6). Moreover, application of LS did not significantly shift the activation curve of CaV3.2 channels. The V0.5 for activation was -53.8 ± 0.4 mV for control condition and -54.9 ± 0.4 mV during LS application, respectively, revealing no significant change in steady-state activation in the presence of LS (n = 6, p = 0.11, Fig 3B). In addition, fitting of the individual current traces, as presented in Fig 3A, revealed that neither activation nor inactivation kinetics of CaV3.2 channels were changed after Lavender treatment (Fig 3C and 3D). Similar results were obtained with 50 μg/ml LA Miller essential oil (Fig 3E, n = 5) and 100 μM Linalool (Fig 3F, n = 6). Inhibition of CaV3.2 currents following treatment with LA Miller essential oil and Linalool was conserved over the complete range of test potentials. Also, the threshold potential for activation and the membrane potential of the maximum peak current were the same before and during the application of LA Miller, with no significant shift in the activation curve of CaV3.2 currents (V0.5Ctrl = -54.8 ± 0.4 mV and V0.5LAMiller = -54.1 ± 0.3 mV, n = 5, p = 0.19), and Linalool (V0.5Ctrl = -50.5 ± 0.7 mV and V0.5Linalool = -52.3 ± 0.8 mV, n = 6, p = 0.14). Fig 3 Fig 3 Lavandula stoechas, Lavandula angustifolia and Linalool do not affect activation of CaV3.2 channels. Effects of Lavandula on CaV3.2 current steady-state inactivation We next examined whether Lavender and its constituents could modify the steady-state inactivation properties of CaV3.2 channels. A representative family of CaV3.2 currents evoked by the protocol designed to measure steady-state inactivation is depicted in Fig 4A before (top traces) and during the application of 30 μg/ml LS (bottom traces). LS (30 μg/ml) produced a depressant action of the maximal conductance of CaV3.2 channels as well as a significant hyperpolarizing shift of steady-state inactivation from -75.8 ± 1.1 mV in control conditions to -81.3 ± 1.0 mV in LS (n = 6, p<0.05, Fig 4B). Similar results were obtained after application of LA Miller (50 μg/ml, Fig 4C) and Linalool (100 μM: ~15 μg/ml, Fig 4D) with a significant shift in the steady-state inactivation from -75.9 ± 0.7 mV to -83.1 ± 0.8 mV for LA Miller (n = 5, p<0.001) and from -74.6 ± 0.7 mV to -81.3 ± 0.6 mV for Linalool (n = 6, p<0.001). These data demonstrate that Lavender constituents inhibit CaV3.2 current by decreasing the maximal conductance of CaV3.2 channels and induce a negative shift of CaV3.2 steady state-inactivation curve, suggesting that Lavender compounds could interact with the inactivated state of TTCCs. In addition, we have investigated the modulation of Cav3.2 current in the presence of 100 μM Linalool at three different frequencies of stimulation (1, 0.2 and 0.033 Hz). These experiments (see Fig 5) show that, although the percentage of inhibition at the steady-state was not significantly different in all three conditions (Fig 5A–5C), the time course of inhibition was significantly faster in experiments done at 1 Hz (time for 50% inhibition ~ 5 s, Fig 5D), compared to slower frequencies: 0.2 Hz (~15 s) and 0.033 Hz (~40 s). These data, support further state-dependent inhibition of Cav3.2 channels by Linalool. Fig 4 Fig 4 Lavandula stoechas, Lavandula angustifolia Miller and Linalool effects on steady-state inactivation of CaV3.2 channels. Fig 5 Fig 5 CaV3.2 channel inhibition by Linalool at various frequency of stimulation. Inhibition of CaV3.2 calcium channels by Rosmarinus officinalis and Rosmarinic acid Next, we studied the effects of Rosmarinus officinalis (RO) and its active principle Rosmarinic acid (RA), a caffeic acid ester compound, on the modulation of CaV3.2 channels. The CaV3.2 current was inhibited by RO in a concentration-dependent manner (Fig 6A, n = 6). CaV3.2 current inhibition by RO yielded an IC50 was of 53.5 ± 3.7 μg/ml with hillslope value of 0.7 ± 0.05 (Fig 6B, n = 6). Furthermore, RA similarly inhibited CaV3.2 current in a concentration-dependent manner. The IC50 value was 48.2 ± 1.4 μM (~18 μg/ml) with a Hillslope value of 1.5 ± 0.2 (Fig 6C and 6D, n = 6). Fig 6 Fig 6 CaV3.2 channel inhibition by Rosmarinus officinalis essential oil. Effect of Rosmarinus officinalis and Rosmarinic acid on CaV3.2 channel activation and inactivation Similar to that described for Lavender compounds, we then studied the effect of RO and RA on CaV3.2 activation and inactivation properties. Analysis of current traces and I-V curves revealed that RO (50 μg/ml) inhibited CaV3.2 currents at all tested potentials without changing the steady-state activation properties (V0.5Control = -52.8 ± 0.4 mV, V0.5RO = -53.5 ± 0.5 mV, n = 7, p = 0.3, Fig 7A). Similar results were obtained after treatment with 50 μM RA (V0.5Control = -51.8 ± 0.6 mV, V0.5RA = -50.6 ± 1.3 mV, n = 6, p = 0.4, Fig 7C). To further elucidate the blocking mechanisms of RO and RA, steady-state inactivation was determined in the absence and presence of these natural substances. These experiments showed that treatment with 50 μg/ml RO both reduced the maximal conductance of CaV3.2 channels and negatively shifted the midpoint of voltage-dependence of inactivation for CaV3.2 towards negative potential (V0.5Control = -73.7 ± 0.9 mV, V0.5RO = -77.8 ± 1.1 mV, n = 7, p<0.05, Fig 7B). The application of 50 μM (~18 μg/ml) of RA induced a shift towards more negative membrane potentials (V0.5Control = -77.4 ± 0.8 mV, V0.5RA = -82.4 ± 1.2 mV, n = 6, p<0.01, Fig 7D). In addition, activation and inactivation kinetics were unchanged after either RO or RA treatment of CaV3.2 channels. Fig 7 Fig 7 Rosmarinus officinalis and Rosmarinic acid affect steady-state inactivation but not activation of CaV3.2 channels. Lavandula steochas and Rosmarinus officinalis preferentially bind to the inactivated state of T-type calcium channels A growing body of reports suggested that TTCC blockers bind to / stabilize the inactivated state of these channels [38, 41, 42]. Indeed, the negative shift induced by Lavender and Rosemary in the channel availability suggests that these natural compounds preferentially bind to the inactivated state of CaV3.2 channels, thus shifting the equilibrium away from states from which channels can open [43]. To evaluate further whether Lavender and Rosemary compounds bind to the inactivated state of TTCCs, we have measured the inhibition of CaV3.2 currents by LS and RS at HPs -100 and -80 mV (Fig 8, upper graphs). If the effects of LS and RO on channel inactivation would contribute significantly to the inhibition of the CaV3 channels, then applying LS and RO to cells voltage-clamped at potentials significantly more negative than -80 mV would produce less current inhibition. As expected, the inhibition by LS (20 μg/ml) was significantly more pronounced when cells were held at HP -80 mV (70 ± 4.4%, n = 6) than at HP -100 mV (51 ± 5.3%, n = 6, p<0.05). Similar data were obtained after the application of RO (20 μg/ml) with 41.3 ± 1.7% of inhibition at HP -80 mV and 23.4 ± 1.7% inhibition at HP -100 mV (n = 6 p<0.01). The efficacy of washout was examined for the two extracts at HPs -100 and -80 mV (Fig 8, lower graphs) and, conversely, washout appeared significantly more efficient at HP -100 mV (LS Washout = 91.6 ± 1.8%, RO Washout = 87.7 ± 3.0%) than at HP -80 mV (LS Washout = 32.6 ± 3.1%), RO Washout = 51.7 ± 2.5%, p<0.001). Taken together, the results suggest that these natural compounds preferentially bind to, and stabilize, CaV3.2 channels in the inactivated state. Fig 8 Fig 8 Efficacy of CaV3.2 inhibition by Lavandula steochas and Rosmarinus officinalis is dependent of the resting membrane potential. Go to: Discussion In this study, we describe several important findings. First, among a selection of Mediterranean medicinal plants including Lavandula stoechas, Rosmarinus officinalis, Ricinus cumunis and Citrullus colocynthis, we have identified that Lavender and Rosemary compounds could significantly inhibit the CaV3.2 TTCCs in a concentration-dependent manner. Importantly, Lavender and Rosemary are widely used medicinal plants. Second, our results provide evidence that their active principles, Linalool and Rosmarinic acid respectively, also inhibit CaV3.2 channels. Third, we report that these compounds induce a negative shift in the steady-state inactivation properties and we show that their inhibitory effect on CaV3.2 channels is significantly enhanced in the range of physiological membrane potential (HP -80 mV), compared to more negative potential (HP -100 mV). Taken together, our findings support a pharmacological modulation of TTCCs by Lavender and Rosemary and we suggest that TTCC inhibition by these natural components may contribute to the neuroprotective and anticonvulsant activities of these medicinal plants. Lavender (Lavandula stoechas, Lavandula angustifolia Miller) and Rosemary (Rosmarinus officinalis) all inhibit the amplitude of CaV3.2 current in a dose-dependent manner. The IC50 values of L. stoechas, L. angustifolia Miller and R. officinalis were estimated to be 16.9, 34.1 and 53.5 μg/ml respectively, suggesting that CaV3.2 channels are more sensitive to Lavandula species and in particular to Lavandula stoechas. Furthermore, Lavender and Rosemary also inhibit the other TTCC isoforms, CaV3.1 and CaV3.3. The IC50 values for LA Miller inhibition were 26.1 ± 4.8 μg/ml (n = 7) for CaV3.1 and 86.2 ± 18.1 μg/ml for CaV3.3 (n = 7). Interestingly, the percentage of inhibition obtained after treatment of the various TTCCs with 10 μg/ml of LA Miller (31% for CaV3.1, 16% for CaV3.2 an 10% for CaV3.3) is similar to that obtained after treatment of HVA, P/Q-type calcium channels with Silexan (25%), a patented active substance produced from L. angustifolia flowers by steam distillation and consisting of the main active constituents linalool and linalyl acetate [10]. Altogether, our data extend previous electrophysiological studies describing the effect of Lavender and its active principle Linalool on other voltage-gated calcium channels [10, 44]. Importantly, we report for the first time to our knowledge, inhibition of voltage-gated calcium channels, in particular TTCCs, by Rosmarinus officinalis and its active principle Rosmarinic acid. Linalool is a monoterpene compound reported to be the major component of Lavender essential oil. It has been reported to trigger glutamate activation in response to NMDA receptors modulation in the cerebral cortex [45] and reduces acetylcholine release at mouse neuromuscular junction by modifying nicotinic receptors kinetics [46], suggesting possible pathways in sedative and anticonvulsant effects in mice [47, 48]. Other studies to investigate the molecular mechanisms associated with linalool therapeutic use revealed that Linalool could interact with voltage-gated channels, in particular voltage-gated calcium channels [10, 44]. Narusuye et al. found that Linalool non-selectively suppressed the voltage-gated currents ICa,L, IK, IA, and IKa in retinal horizontal cells as well as the currents INa, ICa,L, IK, IA, and IK(Ca) in retinal ganglion cells. Fura-2-based calcium imaging technique was used to test the effect of linalool on newt olfactory receptor cells (ORC) expressing both ICa,L and ICa,T [44] and showed that 3 mM Linalool reversibly inhibited calcium currents in ORC by 44.9 ± 2.6%. Similarly, Schuwald et al. reported a decrease on KCl-induced calcium influx in murine synaptosomes after treatment with linalool and linalyl acetate concentrations (1 μM), suggesting potent anxiolytic properties of linalool via modulation of voltage-dependent calcium channels [10]. Our electrophysiological study confirms the inhibition of voltage-gated calcium channels, specifically TTCCs, by Linalool. Linalool attenuates CaV3.2 currents in a dose-dependent manner. The IC50 for Linalool inhibition of TTCCs estimated to be 84 μM is found to be lower than the IC50 obtained for the inhibition of other ionic channels in different preparations. As an example, the IC50 values of Linalool blockade for the voltage-gated sodium is estimated to be around 560 μM [49], suggesting that Linalool is more potent in inhibiting CaV3.2 channels. Rosmarinic acid has been shown to exert neuroprotective effect against antioxidative stress and excitotoxicity and to possess anxiolytic/antidepressive-like effects [20, 50]. The mechanism by which RA exerts its anti-inflammatory effects is not well understood, although it has been shown that RA inhibits lipoxygenase [51] and cyclooxygenase activity [52], block complement activation [53] and T-cell antigen receptor (TCR)-mediated signaling [54]. Whether Rosmarinic acid could modulate ion channels, especially voltage-gated channels, was currently unknown. Our study therefore reveals that TTCCs, are inhibited by Rosmarinus officinalis and Rosmarinic acid in a dose- and voltage-dependent fashion. Consequently, TTCCs may therefore represent a novel molecular target for Rosmarinic acid, although further experiments are needed to characterize the efficacy of Rosmarinic acid to possibly modulate other ion channels. Inhibition of TTCCs is highly dependent on their inactivation state. Analysis of the biophysical properties of CaV3.2 channels before and after Lavender (Lavandula stoechas, Lavandula angustifolia Miller and Linalool) and Rosemary (Rosmarinus officinalis and Rosmarinic acid) treatments showed that these natural compounds not only reduced the maximal conductance of CaV3.2 channels but also shifted the steady-state inactivation properties towards more negative membrane potentials without having effect on the activation properties. Our study describes that inhibition of CaV3.2 channels by Lavender and Rosemary was significantly enhanced for HP -80 mV, compared to HP -100 mV (Fig 7). Indeed, the blocking effect was more efficient at a HP mimicking resting’s membrane potential, at which a large fraction of TTCCs are inactivated [42, 55]. This suggests an interesting mechanism by which Lavender and Rosemary could attenuate the cell excitability by decreasing intracellular calcium concentration and inducing sedative and/or anticonvulsant-like effects, as well as other various therapeutic effects such as neuroprotective properties. Our results showing that these compounds negatively shift the inactivation state suggest that these natural compounds interact with inactivated TTCCs and stabilize them in the inactivated state. This is reminiscent to that reported for phenylalkylamines and dihydropyridines that bind preferentially to the inactivated state of L-type calcium channels (HVA), conferring tissue-selectivity of these drugs that are useful as antihypertensive and antiarrhythmics treatments [56, 57]. Compounds selective on TTCCs could have unexpected therapeutical utility, particularly to treat the various disease states in which TTCCs are up‐regulated. For instance, up-regulation of CaV3.2 channels was observed in both cardiac myocytes and chromaffin cells maintained under chronic hypoxic conditions [58, 59]. Cav3.2 channel overexpression was also found associated to neuroendocrine differentiation of prostate cancer cells [60]. Importantly, TTCCs represent novel interesting molecular targets for pain and epilepsy [31, 33, 43, 61–63]. Inhibition of TTCCs has been reported to play an important role in the therapeutic action of many drugs [64]. For example, Gomora et al. confirmed the hypothesis that the blockade of TTCCs may underlie the therapeutic usefulness of succinimide antiepileptics [65]. In the same context, Tringham and coworkers have identified two high affinity TTCC blockers that were able to attenuate burst firing of thalamic reticular nucleus neurons in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS) [66]. Blockade of TTCCs is suggested to be useful in a wide variety of neurological disorders such as neuropathic pain [67, 68]. Indeed, Jagodic and collaborators have demonstrated that TTCCs are significantly upregulated in small dorsal root ganglion (DRG) during chronic constriction injury (CCI)-induced neuropathy [69]. Therefore, the inhibition of TTCCs by NNC 55–0396, a selective TTCC inhibitor [70] was suggested to be useful in decreasing pre- and postsynaptic transmission and the neuronal activity in anterior cingulate cortex after a CCI leading to the attenuation of neuropathic pain [71]. ABT-639 is a peripherally acting TTCC blocker that selectively inhibits TTCCs in a dose-dependent manner. In preclinical studies, oral administration of ABT-639 was reported to alleviate nociceptive and neuropathic pain in rat models [72]. However, phase 2 clinical studies using microneurography, a relevant technique that assesses abnormal spontaneous activity in C-nociceptors as a marker for spontaneous pain, revealed that administration of ABT-639 100 mg twice daily did not reduce neuropathic pain in diabetic patients [73, 74]. Interestingly, Z944, a potent selective blocker of TTCCs (50–160 nM) was shown to be effective in reducing pain in preclinical models as well as in human patients [75]. Other studies have also suggested TTCCs as interesting molecular targets for natural compounds. Eugenol, a local analgesic used in clinical dentistry that naturally present in cloves (Syzygium aromaticum) modulates TTCCs in a dose-dependent fashion with IC50 of 500 μM. The depressant effect of Eugenol on TTCCs was suggested to inhibit action potentials and the neuronal conduction of sensory signals in TG neurons leading to eugenol pain-relieving action [38]. Furthermore, Ross et al. have demonstrated that Δ9-tetrahydrocannabinol and cannabidiol, the most prevalent biologically active constituents of Cannabis sativa, inhibit recombinant as well as native TTCCs [39]. Interestingly, Cannabidiol is currently under development as an antiepileptic drug [76]. It is likely that attenuation of TTCC conductance causes the decrease in neurotransmitter release mediated by these compounds contributing to the well-known psychoactive actions of cannabinoids, as well as the anti-nociceptive and anticonvulsant properties [39, 76–78]. Go to: Conclusion Our data show that Lavender and Rosemary extracts efficiently inhibit TTCCs by preferentially binding to inactivated channels. Altogether, this study demonstrates that TTCCs represent a novel molecular target for Lavender and Rosemary likely to be involved in some of the Mediterranean medicinal plants’ therapeutic use. Go to: Acknowledgments This work was supported by LabEx 'Ion Channel Science and Therapeutics' to PL. CEA was supported by ‘Bourse du Ministère de l’Enseignement Supérieur et de la Recherche Scientifique’ Maroc, Erasmus Mundus Averroes and L’Oréal-UNESCO for Women in Science Programs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors are grateful to Dr. Isabelle Bidaud for critical help with cell culture. Special thanks to Dr. R. Bouharroud (INRA, Agadir) for plant extraction protocols. Go to: Abbreviations TTCC T-type calcium channel Cav voltage-gated calcium channel HEK human embryonic kidney GFP green fluorescent protein HP holding potential Go to: Funding Statement This work was supported by LabEx 'Ion Channel Science and Therapeutics' to PL. CEA was supported by ‘Bourse du Ministère de l’Enseignement Supérieur et de la Recherche Scientifique’ Maroc, Erasmus Mundus Averroes and L’Oréal-UNESCO for Women in Science Programs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Go to: Data Availability All relevant data are within the paper. Go to: References 1. Petrovska BB. Historical review of medicinal plants' usage. Pharmacogn Rev. 2012;6(11):1–5. doi: 10.4103/0973-7847.95849 ; PubMed Central PMCID: PMCPMC3358962. [PMC free article] [PubMed] 2. Sen T, Samanta SK. Medicinal plants, human health and biodiversity: a broad review. Adv Biochem Eng Biotechnol. 2015;147:59–110. doi: 10.1007/10_2014_273 . [PubMed] 3. Sucher NJ, Carles MC. A pharmacological basis of herbal medicines for epilepsy. Epilepsy Behav. 2015;52(Pt B):308–18. doi: 10.1016/j.yebeh.2015.05.012 . [PubMed] 4. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005;4(3):206–20. doi: 10.1038/nrd1657 . [PubMed] 5. Woronuk G, Demissie Z, Rheault M, Mahmoud S. Biosynthesis and therapeutic properties of Lavandula essential oil constituents. Planta Med. 2011;77(1):7–15. doi: 10.1055/s-0030-1250136 . [PubMed] 6. Koulivand PH, Khaleghi Ghadiri M, Gorji A. Lavender and the nervous system. Evid Based Complement Alternat Med. 2013;2013:681304 doi: 10.1155/2013/681304 ; PubMed Central PMCID: PMCPMC3612440. [PMC free article] [PubMed] 7. Ngo SN, Williams DB, Head RJ. Rosemary and cancer prevention: preclinical perspectives. Crit Rev Food Sci Nutr. 2011;51(10):946–54. doi: 10.1080/10408398.2010.490883 . [PubMed] 8. Cavanagh HM, Wilkinson JM. Biological activities of lavender essential oil. Phytother Res. 2002;16(4):301–8. doi: 10.1002/ptr.1103 . [PubMed] 9. Gilani AH, Aziz N, Khan MA, Shaheen F, Jabeen Q, Siddiqui BS, et al. Ethnopharmacological evaluation of the anticonvulsant, sedative and antispasmodic activities of Lavandula stoechas L. J Ethnopharmacol. 2000;71(1–2):161–7. . [PubMed] 10. Schuwald AM, Noldner M, Wilmes T, Klugbauer N, Leuner K, Muller WE. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One. 2013;8(4):e59998 doi: 10.1371/journal.pone.0059998 ; PubMed Central PMCID: PMCPMC3639265. [PMC free article] [PubMed] 11. Lehrner J, Marwinski G, Lehr S, Johren P, Deecke L. Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office. Physiol Behav. 2005;86(1–2):92–5. doi: 10.1016/j.physbeh.2005.06.031 . [PubMed] 12. Herrero M, Plaza M, Cifuentes A, Ibanez E. Green processes for the extraction of bioactives from Rosemary: Chemical and functional characterization via ultra-performance liquid chromatography-tandem mass spectrometry and in-vitro assays. J Chromatogr A. 2010;1217(16):2512–20. doi: 10.1016/j.chroma.2009.11.032 . [PubMed] 13. Xiao C, Dai H, Liu H, Wang Y, Tang H. Revealing the metabonomic variation of rosemary extracts using 1H NMR spectroscopy and multivariate data analysis. J Agric Food Chem. 2008;56(21):10142–53. doi: 10.1021/jf8016833 . [PubMed] 14. Gonzalez-Trujano ME, Pena EI, Martinez AL, Moreno J, Guevara-Fefer P, Deciga-Campos M, et al. Evaluation of the antinociceptive effect of Rosmarinus officinalis L. using three different experimental models in rodents. J Ethnopharmacol. 2007;111(3):476–82. doi: 10.1016/j.jep.2006.12.011 . [PubMed] 15. Takaki I, Bersani-Amado LE, Vendruscolo A, Sartoretto SM, Diniz SP, Bersani-Amado CA, et al. Anti-inflammatory and antinociceptive effects of Rosmarinus officinalis L. essential oil in experimental animal models. J Med Food. 2008;11(4):741–6. doi: 10.1089/jmf.2007.0524 . [PubMed] 16. Park SE, Kim S, Sapkota K, Kim SJ. Neuroprotective effect of Rosmarinus officinalis extract on human dopaminergic cell line, SH-SY5Y. Cell Mol Neurobiol. 2010;30(5):759–67. doi: 10.1007/s10571-010-9502-3 . [PubMed] 17. Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia. 2013;91:261–71. doi: 10.1016/j.fitote.2013.09.012 . [PubMed] 18. Rocha J, Eduardo-Figueira M, Barateiro A, Fernandes A, Brites D, Bronze R, et al. Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic Clin Pharmacol Toxicol. 2015;116(5):398–413. doi: 10.1111/bcpt.12335 . [PubMed] 19. Gamaro GD, Suyenaga E, Borsoi M, Lermen J, Pereira P, Ardenghi P. Effect of rosmarinic and caffeic acids on inflammatory and nociception process in rats. ISRN Pharmacol. 2011;2011:451682 doi: 10.5402/2011/451682 ; PubMed Central PMCID: PMCPMC3197075. [PMC free article] [PubMed] 20. Jin X, Liu P, Yang F, Zhang YH, Miao D. Rosmarinic acid ameliorates depressive-like behaviors in a rat model of CUS and Up-regulates BDNF levels in the hippocampus and hippocampal-derived astrocytes. Neurochem Res. 2013;38(9):1828–37. doi: 10.1007/s11064-013-1088-y . [PubMed] 21. Huang L, Abuhamdah S, Howes MJ, Dixon CL, Elliot MS, Ballard C, et al. Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: focus on ligand-gated channels. J Pharm Pharmacol. 2008;60(11):1515–22. doi: 10.1211/jpp/60.11.0013 . [PubMed] 22. Chioca LR, Ferro MM, Baretta IP, Oliveira SM, Silva CR, Ferreira J, et al. Anxiolytic-like effect of lavender essential oil inhalation in mice: participation of serotonergic but not GABAA/benzodiazepine neurotransmission. J Ethnopharmacol. 2013;147(2):412–8. doi: 10.1016/j.jep.2013.03.028 . [PubMed] 23. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev. 2003;83(1):117–61. doi: 10.1152/physrev.00018.2002 . [PubMed] 24. Llinas RR, Steriade M. Bursting of thalamic neurons and states of vigilance. J Neurophysiol. 2006;95(6):3297–308. doi: 10.1152/jn.00166.2006 . [PubMed] 25. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 2005;57(4):397–409. doi: 10.1124/pr.57.4.4 . [PubMed] 26. Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci. 1999;19(6):1895–911. . [PubMed] 27. Anderson MP, Mochizuki T, Xie J, Fischler W, Manger JP, Talley EM, et al. Thalamic Cav3.1 T-type Ca2+ channel plays a crucial role in stabilizing sleep. Proc Natl Acad Sci U S A. 2005;102(5):1743–8. doi: 10.1073/pnas.0409644102 ; PubMed Central PMCID: PMCPMC547889. [PMC free article] [PubMed] 28. Chemin J, Monteil A, Briquaire C, Richard S, Perez-Reyes E, Nargeot J, et al. Overexpression of T-type calcium channels in HEK-293 cells increases intracellular calcium without affecting cellular proliferation. FEBS letters. 2000;478(1–2):166–72. . [PubMed] 29. Chemin J, Nargeot J, Lory P. Neuronal T-type alpha 1H calcium channels induce neuritogenesis and expression of high-voltage-activated calcium channels in the NG108-15 cell line. J Neurosci. 2002;22(16):6856–62. . [PubMed] 30. Chemin J, Monteil A, Perez-Reyes E, Bourinet E, Nargeot J, Lory P. Specific contribution of human T-type calcium channel isotypes (alpha(1G), alpha(1H) and alpha(1I)) to neuronal excitability. J Physiol. 2002;540(Pt 1):3–14. doi: 10.1113/jphysiol.2001.013269 ; PubMed Central PMCID: PMCPMC2290209. [PMC free article] [PubMed] 31. Cain SM, Snutch TP. T-type calcium channels in burst-firing, network synchrony, and epilepsy. Biochim Biophys Acta. 2013;1828(7):1572–8. doi: 10.1016/j.bbamem.2012.07.028 . [PubMed] 32. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. The EMBO journal. 2005;24(2):315–24. doi: 10.1038/sj.emboj.7600515 ; PubMed Central PMCID: PMCPMC545807. [PMC free article] [PubMed] 33. Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol. 2011;163(3):484–95. doi: 10.1111/j.1476-5381.2011.01256.x ; PubMed Central PMCID: PMCPMC3101611. [PMC free article] [PubMed] 34. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. The EMBO journal. 2001;20(24):7033–40. doi: 10.1093/emboj/20.24.7033 ; PubMed Central PMCID: PMCPMC125779. [PMC free article] [PubMed] 35. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, et al. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci. 2009;29(42):13106–14. doi: 10.1523/JNEUROSCI.2919-09.2009 . [PubMed] 36. Cazade M, Nuss CE, Bidaud I, Renger JJ, Uebele VN, Lory P, et al. Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2. Mol Pharmacol. 2014;85(2):218–25. doi: 10.1124/mol.113.089581 . [PubMed] 37. Chuang RS, Jaffe H, Cribbs L, Perez-Reyes E, Swartz KJ. Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat Neurosci. 1998;1(8):668–74. doi: 10.1038/3669 . [PubMed] 38. Seo H, Li HY, Perez-Reyes E, Lee JH. Effects of eugenol on T-type Ca2+ channel isoforms. J Pharmacol Exp Ther. 2013;347(2):310–7. doi: 10.1124/jpet.113.207936 . [PubMed] 39. Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283(23):16124–34. doi: 10.1074/jbc.M707104200 ; PubMed Central PMCID: PMCPMC3259625. [PMC free article] [PubMed] 40. Enyeart JA, Liu H, Enyeart JJ. Curcumin inhibits ACTH- and angiotensin II-stimulated cortisol secretion and Ca(v)3.2 current. J Nat Prod. 2009;72(8):1533–7. doi: 10.1021/np900227x ; PubMed Central PMCID: PMCPMC2853174. [PMC free article] [PubMed] 41. Traboulsie A, Chemin J, Kupfer E, Nargeot J, Lory P. T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol Pharmacol. 2006;69(6):1963–8. doi: 10.1124/mol.105.020842 . [PubMed] 42. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, Hanck DA. Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000;295(1):302–8. . [PubMed] 43. Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015;67(4):821–70. doi: 10.1124/pr.114.009654 ; PubMed Central PMCID: PMCPMC4630564. [PMC free article] [PubMed] 44. Narusuye K, Kawai F, Matsuzaki K, Miyachi E. Linalool suppresses voltage-gated currents in sensory neurons and cerebellar Purkinje cells. J Neural Transm (Vienna). 2005;112(2):193–203. doi: 10.1007/s00702-004-0187-y . [PubMed] 45. Elisabetsky E, Brum LF, Souza DO. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine. 1999;6(2):107–13. . [PubMed] 46. Re L, Barocci S, Sonnino S, Mencarelli A, Vivani C, Paolucci G, et al. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res. 2000;42(2):177–82. doi: 10.1006/phrs.2000.0671 . [PubMed] 47. Linck VM, da Silva AL, Figueiro M, Piato AL, Herrmann AP, Dupont Birck F, et al. Inhaled linalool-induced sedation in mice. Phytomedicine. 2009;16(4):303–7. doi: 10.1016/j.phymed.2008.08.001 . [PubMed] 48. Linck VM, da Silva AL, Figueiro M, Caramao EB, Moreno PR, Elisabetsky E. Effects of inhaled Linalool in anxiety, social interaction and aggressive behavior in mice. Phytomedicine. 2010;17(8–9):679–83. doi: 10.1016/j.phymed.2009.10.002 . [PubMed] 49. Kawai F, Kurahashi T, Kaneko A. T-type Ca2+ channel lowers the threshold of spike generation in the newt olfactory receptor cell. J Gen Physiol. 1996;108(6):525–35. ; PubMed Central PMCID: PMCPMC2229340. [PMC free article] [PubMed] 50. Fallarini S, Miglio G, Paoletti T, Minassi A, Amoruso A, Bardelli C, et al. Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death. Br J Pharmacol. 2009;157(6):1072–84. doi: 10.1111/j.1476-5381.2009.00213.x ; PubMed Central PMCID: PMCPMC2737666. [PMC free article] [PubMed] 51. Kimura Y, Okuda H, Okuda T, Hatano T, Arichi S. Studies on the activities of tannins and related compounds, X. Effects of caffeetannins and related compounds on arachidonate metabolism in human polymorphonuclear leukocytes. J Nat Prod. 1987;50(3):392–9. . [PubMed] 52. Kelm MA, Nair MG, Strasburg GM, DeWitt DL. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine. 2000;7(1):7–13. doi: 10.1016/S0944-7113(00)80015-X . [PubMed] 53. Sahu A, Rawal N, Pangburn MK. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem Pharmacol. 1999;57(12):1439–46. . [PubMed] 54. Won J, Hur YG, Hur EM, Park SH, Kang MA, Choi Y, et al. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur J Immunol. 2003;33(4):870–9. doi: 10.1002/eji.200323010 . [PubMed] 55. Huguenard JR. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol. 1996;58:329–48. doi: 10.1146/annurev.ph.58.030196.001553 . [PubMed] 56. Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol. 1984;24:387–423. doi: 10.1146/annurev.pa.24.040184.002131 . [PubMed] 57. Hering S, Aczel S, Kraus RL, Berjukow S, Striessnig J, Timin EN. Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc Natl Acad Sci U S A. 1997;94(24):13323–8. ; PubMed Central PMCID: PMCPMC24307. [PMC free article] [PubMed] 58. Gonzalez-Rodriguez P, Falcon D, Castro MJ, Urena J, Lopez-Barneo J, Castellano A. Hypoxic induction of T-type Ca(2+) channels in rat cardiac myocytes: role of HIF-1alpha and RhoA/ROCK signalling. J Physiol. 2015;593(21):4729–45. doi: 10.1113/JP271053 ; PubMed Central PMCID: PMCPMC4626545. [PMC free article] [PubMed] 59. Carabelli V, Marcantoni A, Comunanza V, de Luca A, Diaz J, Borges R, et al. Chronic hypoxia up-regulates alpha1H T-type channels and low-threshold catecholamine secretion in rat chromaffin cells. J Physiol. 2007;584(Pt 1):149–65. doi: 10.1113/jphysiol.2007.132274 ; PubMed Central PMCID: PMCPMC2277059. [PMC free article] [PubMed] 60. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem. 2002;277(13):10824–33. doi: 10.1074/jbc.M108754200 . [PubMed] 61. Powell KL, Cain SM, Snutch TP, O'Brien TJ. Low threshold T-type calcium channels as targets for novel epilepsy treatments. Br J Clin Pharmacol. 2014;77(5):729–39. doi: 10.1111/bcp.12205 ; PubMed Central PMCID: PMCPMC4004393. [PMC free article] [PubMed] 62. Tsakiridou E, Bertollini L, de Curtis M, Avanzini G, Pape HC. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. J Neurosci. 1995;15(4):3110–7. . [PubMed] 63. Sakkaki S, Gangarossa G, Lerat B, Francon D, Forichon L, Chemin J, et al. Blockade of T-type calcium channels prevents tonic-clonic seizures in a maximal electroshock seizure model. Neuropharmacology. 2016;101:320–9. doi: 10.1016/j.neuropharm.2015.09.032 . [PubMed] 64. Lory P, Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets. 2007;11(5):717–22. doi: 10.1517/14728222.11.5.717 . [PubMed] 65. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001;60(5):1121–32. . [PubMed] 66. Tringham E, Powell KL, Cain SM, Kuplast K, Mezeyova J, Weerapura M, et al. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Sci Transl Med. 2012;4(121):121ra19 doi: 10.1126/scitranslmed.3003120 . [PubMed] 67. Llinas RR, Ribary U, Jeanmonod D, Kronberg E, Mitra PP. Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci U S A. 1999;96(26):15222–7. ; PubMed Central PMCID: PMCPMC24801. [PMC free article] [PubMed] 68. Berger ND, Gadotti VM, Petrov RR, Chapman K, Diaz P, Zamponi GW. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors. Mol Pain. 2014;10:77 doi: 10.1186/1744-8069-10-77 ; PubMed Central PMCID: PMCPMC4271433. [PMC free article] [PubMed] 69. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol. 2008;99(6):3151–6. doi: 10.1152/jn.01031.2007 ; PubMed Central PMCID: PMCPMC2667888. [PMC free article] [PubMed] 70. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, et al. NNC 55–0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2, 3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther. 2004;309(1):193–9. doi: 10.1124/jpet.103.060814 . [PubMed] 71. Shen FY, Chen ZY, Zhong W, Ma LQ, Chen C, Yang ZJ, et al. Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex. Mol Pain. 2015;11:7 doi: 10.1186/s12990-015-0008-3 ; PubMed Central PMCID: PMCPMC4357203. [PMC free article] [PubMed] 72. Jarvis MF, Scott VE, McGaraughty S, Chu KL, Xu J, Niforatos W, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol. 2014;89(4):536–44. doi: 10.1016/j.bcp.2014.03.015 . [PubMed] 73. Ziegler D, Duan WR, An G, Thomas JW, Nothaft W. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain. 2015;156(10):2013–20. doi: 10.1097/j.pain.0000000000000263 ; PubMed Central PMCID: PMCPMC4770341. [PMC free article] [PubMed] 74. Serra J, Duan WR, Locke C, Sola R, Liu W, Nothaft W. Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015;156(11):2175–83. doi: 10.1097/j.pain.0000000000000249 . [PubMed] 75. Lee M. Z944: a first in class T-type calcium channel modulator for the treatment of pain. J Peripher Nerv Syst. 2014;19 Suppl 2:S11–2. doi: 10.1111/jns.12080_2 . [PubMed] 76. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141. doi: 10.1016/j.eplepsyres.2015.01.001 . [PubMed] 77. Hill TD, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679–92. doi: 10.1111/bph.12321 ; PubMed Central PMCID: PMCPMC3792005. [PMC free article] [PubMed] 78. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth. 2008;101(1):59–68. doi: 10.1093/bja/aen119 . [PubMed] Articles from PLoS ONE are provided here courtesy of Public Library of Science